Pozen gains on Phase III cardiovascular data

Pozen Inc. (NASDAQ:POZN) gained as much as 19% on Thursday before closing up 9%, or $0.42, to $5.22 after PA32540 met the primary endpoint in two Phase III trials for the secondary prevention of cardio- and cerebrovascular events in patients at risk for developing aspirin-associated gastric ulcers. In each trial, the product significantly reduced the cumulative incidence of gastric ulcers over six months vs. once-daily 325 mg enteric-coated aspirin. ...